Molecular monitoring and stepwise preemptive therapy for Epstein–Barr virus viremia after allogeneic stem cell transplantation
Authors:
Open Access
- 6 April 2013
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 88 (7) , 550-555
Abstract
The optimal preemptive therapy for Epstein–Barr virus (EBV)‐associated diseases remains under discussion. We developed a stepwise preemptive therapy (antiviral agents and reduction of immunosuppressants [RI] followed by rituximab) for EBV viremia, based on duration of EBV viremia and changes of viral loads. The blood EBV‐DNA loads were regularly monitored by quantitative real‐time polymerase chain reaction in 251 recipients undergoing allogeneic stem cell transplantation. The 3‐year cumulative incidence of EBV viremia and EBV‐associated diseases were 31.1% ± 3.1% and 15.6% ± 2.5%, which rose steeply with greater numbers of major risk factors. Of the 64 patients undergoing first‐step preemption, 24 achieved complete response (CR) and 40 showed no response, including 25 progressing to EBV‐associated diseases. The effective rates of antiviral agents and RI plus antiviral agents were 2/16 and 22/48 (P = 0.017). Fourteen achieved CR and one progressed to lymphoproliferative disease in the 15 patients undergoing rituximab preemption. Of the 26 patients progressing to EBV‐associated diseases during preemptive therapy, 20 obtained CR in the 23 cases with rituximab‐based treatments. The preemptive efficacy of RI plus antiviral agents was correlated with the numbers of major risk factors (rs = −0.298; P = 0.04). B‐cell reconstitution was significantly delayed for at least 6 months in patients with rituximab preemption. The risk of herpesvirus infection was similar in patients who showed effective progress to first‐step and rituximab preemption (P = 0.094). RI plus antiviral agents could be given priority to low‐risk patients, whereas more frequent monitoring of blood EBV‐DNA and earlier preemptive rituximab should be advocated in high‐risk patients. Am. J. Hematol. 88:550–555, 2013.Keywords
This publication has 36 references indexed in Scilit:
- Allogeneic hematopoietic stem cell transplantation in China: where we are and where to goJournal of Hematology & Oncology, 2012
- Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantationTransplant Infectious Disease, 2010
- The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft‐versus‐host diseaseAmerican Journal of Hematology, 2008
- Novel strategies for relapsed and refractory acute myeloid leukemiaCurrent Opinion in Hematology, 2008
- Chronic GvHD decreases antiviral immune responses in allogeneic BMTBlood, 2007
- Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reactionScandinavian Journal of Infectious Diseases, 2007
- Psychiatric symptoms and cognitive dysfunction caused by Epstein–Barr virus-induced encephalitisEuropean Psychiatry, 2006
- Treatment and outcomes of post‐transplant lymphoproliferative disease: A single institution studyAmerican Journal of Hematology, 2006
- Editorial Commentary:Epstein‐Barr Virus Infection after Stem Cell Transplantation: New Concepts Are Needed Both for the Donor and the RecipientClinical Infectious Diseases, 2006
- Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCTBlood, 2001